UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

The Discovery of Fluoxetine Hydrochloride (Prozac)

Nature reviews. Drug discovery, 2005-09, Vol.4 (9), p.764-774

2005

Volltextzugriff (PDF)

Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection

Pharmacological reviews, 2008-09, Vol.60 (3), p.358-403

2008

Volltextzugriff (PDF)

A review of the abuse potential assessment of atomoxetine: a nonstimulant medication for attention-deficit/hyperactivity disorder

Psychopharmacology, 2013-03, Vol.226 (2), p.189-200

2013

Volltextzugriff (PDF)

Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor

The Journal of pharmacology and experimental therapeutics, 2002-06, Vol.301 (3), p.1020-1024

2002

Volltextzugriff (PDF)

Antipsychotic-like effect of the muscarinic acetylcholine receptor agonist BuTAC in non-human primates

PloS one, 2015-04, Vol.10 (4), p.e0122722-e0122722

2015

Volltextzugriff (PDF)

Therapeutic Opportunities for Muscarinic Receptors in the Central Nervous System

Journal of medicinal chemistry, 2000-11, Vol.43 (23), p.4333-4353

2000

Volltextzugriff (PDF)

Radioreceptor Binding Profile of the Atypical Antipsychotic Olanzapine

Neuropsychopharmacology (New York, N.Y.), 1996-02, Vol.14 (2), p.87-96

1996

Volltextzugriff (PDF)

Muscarinic mechanisms in psychotic disorders

Handbook of experimental pharmacology, 2012 (213), p.233

2012

Volltextzugriff (PDF)

Atomoxetine Increases Extracellular Levels of Norepinephrine and Dopamine in Prefrontal Cortex of Rat: A Potential Mechanism for Efficacy in Attention Deficit/Hyperactivity Disorder

Neuropsychopharmacology (New York, N.Y.), 2002-11, Vol.27 (5), p.699-711

2002

Volltextzugriff (PDF)

Case history: the discovery of fluoxetine hydrochloride (Prozac)

Nature reviews. Drug discovery, 2005-09, Vol.4 (9), p.764-774

2005

Volltextzugriff (PDF)

Duloxetine Increases Serotonin and Norepinephrine Availability in Healthy Subjects: A Double-Blind, Controlled Study

Neuropsychopharmacology, 2003-09, Vol.28 (9), p.1685-1693

2003

Volltextzugriff (PDF)

Viloxazine Increases Extracellular Concentrations of Norepinephrine, Dopamine, and Serotonin in the Rat Prefrontal Cortex at Doses Relevant for the Treatment of Attention-Deficit/Hyperactivity Disorder

Journal of experimental pharmacology, 2024, Vol.16, p.13-24

2024

Volltextzugriff (PDF)

Comparative Affinity of Duloxetine and Venlafaxine for Serotonin and Norepinephrine Transporters in vitro and in vivo, Human Serotonin Receptor Subtypes, and Other Neuronal Receptors

Neuropsychopharmacology (New York, N.Y.), 2001-12, Vol.25 (6), p.871-880

2001

Volltextzugriff (PDF)

Minocycline Prevents Nigrostriatal Dopaminergic Neurodegeneration in the MPTP Model of Parkinson's Disease

Proceedings of the National Academy of Sciences - PNAS, 2001-12, Vol.98 (25), p.14669-14674

2001

Volltextzugriff (PDF)

Biopharmaceutical Characterization, Metabolism, and Brain Penetration of the Triple Reuptake Inhibitor Amitifadine

Drug metabolism letters, 2013-03, Vol.7 (1), p.23-33

2013

Volltextzugriff (PDF)

The dual transporter inhibitor duloxetine: a review of its preclinical pharmacology, pharmacokinetic profile, and clinical results in depression

Current pharmaceutical design, 2005-05, Vol.11 (12), p.1475-1493

2005

Volltextzugriff (PDF)

Fluoxetine, but not other selective serotonin uptake inhibitors, increases norepinephrine and dopamine extracellular levels in prefrontal cortex

Psychopharmacologia, 2002-04, Vol.160 (4), p.353-361

2002

Volltextzugriff (PDF)

Cholinergic dilation of cerebral blood vessels is abolished in M5 muscarinic acetylcholine receptor knockout mice

Proceedings of the National Academy of Sciences - PNAS, 2001-11, Vol.98 (24), p.14096-14101

2001

Volltextzugriff (PDF)

Synergistic Effects of Olanzapine and Other Antipsychotic Agents in Combination with Fluoxetine on Norepinephrine and Dopamine Release in Rat Prefrontal Cortex

Neuropsychopharmacology (New York, N.Y.), 2000-09, Vol.23 (3), p.250-262

2000

Volltextzugriff (PDF)

R-fluoxetine Increases Extracellular DA, NE, As Well As 5-HT in Rat Prefrontal Cortex and Hypothalamus: An in vivo Microdialysis and Receptor Binding Study

Neuropsychopharmacology (New York, N.Y.), 2002-12, Vol.27 (6), p.949-959

2002

Volltextzugriff (PDF)

Preclinical pharmacology of FMPD [6-fluoro-10-[3-(2-methoxyethyl)-4-methyl-piperazin-1-yl]-2-methyl-4H-3-thia-4,9-diaza-benzo[f]azulene]: a potential novel antipsychotic with lower histamine H1 receptor affinity than olanzapine

The Journal of pharmacology and experimental therapeutics, 2005-12, Vol.315 (3), p.1265

2005

Volltextzugriff (PDF)

Muscarinic receptors as a target for drugs treating schizophrenia

Current drug targets. CNS & neurological disorders, 2002-04, Vol.1 (2), p.163-181

2002

Volltextzugriff (PDF)

Zonisamide Prevents Olanzapine-Associated Hyperphagia, Weight Gain, and Elevated Blood Glucose in Rats

Neuropsychopharmacology (New York, N.Y.), 2008-11, Vol.33 (12), p.2922-2933

2008

Volltextzugriff (PDF)

Amantadine for weight gain associated with olanzapine treatment

European neuropsychopharmacology, 2005, Vol.15 (1), p.13-21

2005

Volltextzugriff (PDF)

M1 muscarinic receptor signaling in mouse hippocampus and cortex

Brain research, 2002-07, Vol.944 (1), p.82-89

2002

Volltextzugriff (PDF)

1 – 25 von 78

Suche als RSS-Feed

Aktive Filter

KollektionJournals@Ovid Complete

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(76)
Mit Volltextzugriff
(59)

Publikationsform

Artikel
(77)
Buchkapitel
(1)

Sprache

Englisch
(78)

Erscheinungsjahr

n.n

Thema

Science & Technology
(45)
Animals
(42)
Life Sciences & Biomedicine
(42)
Pharmacology & Pharmacy
(31)
Male
(29)
Biological And Medical Sciences
(28)
Humans
(26)
Medical Sciences
(24)
Pharmacology. Drug Treatments
(22)
Rats
(22)
Neuropharmacology
(21)
Neurosciences
(19)
Neurosciences & Neurology
(19)
Psychopharmacology
(17)
Psychiatry
(16)
Mice
(15)
Psychology. Psychoanalysis. Psychiatry
(15)
Rats, Sprague-Dawley
(14)
Muscarinic Agonists - Pharmacology
(12)
Receptors, Muscarinic - Drug Effects
(12)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

The Discovery of Fluoxetine Hydrochloride (Prozac)

Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection

A review of the abuse potential assessment of atomoxetine: a nonstimulant medication for attention-deficit/hyperactivity disorder

Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor

Antipsychotic-like effect of the muscarinic acetylcholine receptor agonist BuTAC in non-human primates

Therapeutic Opportunities for Muscarinic Receptors in the Central Nervous System

Radioreceptor Binding Profile of the Atypical Antipsychotic Olanzapine

Muscarinic mechanisms in psychotic disorders

Atomoxetine Increases Extracellular Levels of Norepinephrine and Dopamine in Prefrontal Cortex of Rat: A Potential Mechanism for Efficacy in Attention Deficit/Hyperactivity Disorder

Case history: the discovery of fluoxetine hydrochloride (Prozac)

Duloxetine Increases Serotonin and Norepinephrine Availability in Healthy Subjects: A Double-Blind, Controlled Study

Viloxazine Increases Extracellular Concentrations of Norepinephrine, Dopamine, and Serotonin in the Rat Prefrontal Cortex at Doses Relevant for the Treatment of Attention-Deficit/Hyperactivity Disorder

Comparative Affinity of Duloxetine and Venlafaxine for Serotonin and Norepinephrine Transporters in vitro and in vivo, Human Serotonin Receptor Subtypes, and Other Neuronal Receptors

Minocycline Prevents Nigrostriatal Dopaminergic Neurodegeneration in the MPTP Model of Parkinson's Disease

Biopharmaceutical Characterization, Metabolism, and Brain Penetration of the Triple Reuptake Inhibitor Amitifadine

The dual transporter inhibitor duloxetine: a review of its preclinical pharmacology, pharmacokinetic profile, and clinical results in depression

Fluoxetine, but not other selective serotonin uptake inhibitors, increases norepinephrine and dopamine extracellular levels in prefrontal cortex

Cholinergic dilation of cerebral blood vessels is abolished in M5 muscarinic acetylcholine receptor knockout mice

Synergistic Effects of Olanzapine and Other Antipsychotic Agents in Combination with Fluoxetine on Norepinephrine and Dopamine Release in Rat Prefrontal Cortex

R-fluoxetine Increases Extracellular DA, NE, As Well As 5-HT in Rat Prefrontal Cortex and Hypothalamus: An in vivo Microdialysis and Receptor Binding Study

Preclinical pharmacology of FMPD [6-fluoro-10-[3-(2-methoxyethyl)-4-methyl-piperazin-1-yl]-2-methyl-4H-3-thia-4,9-diaza-benzo[f]azulene]: a potential novel antipsychotic with lower histamine H1 receptor affinity than olanzapine

Muscarinic receptors as a target for drugs treating schizophrenia

Zonisamide Prevents Olanzapine-Associated Hyperphagia, Weight Gain, and Elevated Blood Glucose in Rats

Amantadine for weight gain associated with olanzapine treatment

M1 muscarinic receptor signaling in mouse hippocampus and cortex

Aktive Filter

Suchergebnisse filtern